Newsfeeds - Spark Newswire

1 minute read

Intercept Pharmaceuticals: Q2 Earnings Insights

Today, 9:12 PM

Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) moved higher by 3.6% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 82.81% year over year to ($0.33), which beat the estimate of ($1.21).

ICPT

22 minute read

Earnings Scheduled For July 29, 2021

By Benzinga Insights

Today, 9:12 PM

Companies Reporting Before The Bell • Smith & Nephew (NYSE:SNN) is projected to report earnings for its second quarter.

5 minute read

The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer’s Conference, IPOs and More

By Shanthi Rexaline

Today, 9:12 PM

Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start to the pharma reporting season.

ABBV

1 minute read

Legal
News

Intercept Pharmaceuticals Granted U.S. Patent Titled ‘Methods and intermediates for the preparation of bile acid derivatives’

By Benzinga Newsdesk

Today, 9:12 PM

https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=5485&f=G&l=50&d=PTXT&p=110&S1=20210720&OS=20210720&RS=20210720

ICPT

1 minute read

Uncategorized

FDA Restricts Use Of Intercept’s Ocaliva In Liver Disease with Advanced Cirrhosis Citing Risk Of Serious Liver Injury

By Vandana Singh

Today, 9:12 PM

The FDA has issued a statement restricting the use of Intercept Pharmaceuticals Inc’s (NASDAQ:ICPT) Ocaliva (obeticholic acid) in primary biliary cholangitis (PBC)…

ICPT